At the news
? NEUTRALIMPACT 4/10 8-K filed Mar 5, 2026 at 17:02 ET
Outlook Therapeutics held a Type A meeting with the FDA to discuss the Complete Response Letter for its ONS-5010 (LYTENAVA) biologics license application for wet AMD. The company stated it remains committed to working with the FDA to clarify the path forward for potential approval, but no resolution or timeline was provided.
- Outlook Therapeutics conducted a Type A meeting with the FDA on March 5, 2026, regarding the CRL issued on December 30, 2025 for ONS-5010/LYTENAVA.
- The meeting focused on the FDA's concern about 'substantial evidence of effectiveness' for the BLA.
- The company reiterated that NORSE TWO met primary and key secondary endpoints and that NORSE EIGHT and other data support confirmatory evidence of efficacy and safety.
- No decision, resolution, or timeline for approval was announced; the company will continue discussions with the FDA.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access